In glioblastoma, TLK2 overexpression correlates with poor clinical outcomes and drives cell proliferation, migration, invasion, and epithelial-mesenchymal transition through the SRC signaling pathway, while silencing TLK2 has opposite effects (Lin et al., 2019). The gene discussed is SRC; the disease is glioblastoma.